BBDDL2059 - Network of Cancer Research

BBDDL2059 is a EZH2 Inhibitor for Cancer Research

Louis Gilman September 11, 2023

BBDDL2059 is a highly potent and selective covalent inhibitor of EZH2.

BI 7446 is a STING Agonist for Immuno-oncology Research

Gastric Cancer Obesity

JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research

Multiple Myeloma Myeloma

OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research

autoimmune disease

INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research